ライフサイエンスコーパス: multimodality

1 all with the inherent advantages of the XPCI multimodality.

2 ribe a novel computational approach based on multimodality, 3D whole-tumor imaging data acquired from

3 y (CT)-guided interventional procedures in a multimodality abdominal phantom.

4 The relationship between cognition and the multimodality AD biomarker was stronger in individuals w

5 We also discuss 'multimodalities' addressing postoperative nausea and vom

6 n of fluorescent and nuclear contrast into a multimodality agent builds on these capabilities by addi

7 A single multimodality agent that can be used with magnetic reson

8 the first 124I-labeled photosensitizer as a "multimodality agent", which could further be improved by

9 Methods This is a secondary analysis of the Multimodality Analysis and Radiologic Guidance in Breast

10 Data multimodality and abundance of zero read counts are the

11 Research supports the need for multimodality and individualized treatment programs.

12 ments are aiming to achieve high-resolution, multimodality and lifetime-based in vivo fluorescence im

13 resonance imaging in clinical practice, and multimodality and molecular imaging as new technologies.

14 future of tumor angiogenesis imaging lies in multimodality and nanoparticle-based approaches, imaging

15 Medical imaging with multimodality and whole-body technologies has continuous

16 ell RNA-seq expression profiles, capture its multimodality, and conduct differential gene expression

17 ingle experiments to large multi-instrument, multimodality, and multicenter studies.

18 activation, extended imaging and theranostic multimodality, and synergistic application of multiple t

19 er chemotherapy alone (44.3 months) or after multimodality approach (47.4 months; P = .81).

20 ity in subjects with carotid plaques using a multimodality approach combining FDG positron emission t

21 tion of contrast material-enhanced US into a multimodality approach for diagnosis of HCC and its bene

22 A multimodality approach has allowed operators to overcome

23 is prospective longitudinal study, we used a multimodality approach including positron emission tomog

24 Accordingly, a multimodality approach is increasingly used for diagnost

25 A multimodality approach paying attention to a range of po

26 n reducing complications and deaths within a multimodality approach remains substantial and should be

27 he future of HFpEF risk assessment lies in a multimodality approach that combines the relevant echoca

28 In this study, we took a multimodality approach to evaluate the phenotypic effect

29 It is hoped that a multimodality approach, which incorporates targeted ther

30 ) to systemic treatment either alone or with multimodality approach.

31 nefit was achieved by radical surgery within multimodality approaches (HR 0.911, 95% CI 0.53-1.58; P

32 squamous cell carcinoma (HNSCC) and current multimodality approaches impart significant toxicities.

33 We further discuss opportunities provided by multimodality approaches such as PET/MRI and PET/optical

34 However, emerging multimodality approaches such as positron emission tomog

35 t distant goal, attention has shifted toward multimodality approaches to cancer therapy, sometimes co

36 Multimodality approaches to colorectal imaging that inco

37 n the 1970s with the broader introduction of multimodality approaches, often including combination ch

38 ccompanied by drastic cross validation using multimodality approaches.

39 his study sought to evaluate the impact of a multimodality-appropriate use criteria decision support

40 sected nodes, 0.76; P=0.007), but not in the multimodality arm (hazard ratio 1.00; P=0.98).

41 This multimodality attack on the same tumor antigen may have

42 cular concerns associated with contemporary, multimodality BC treatment and illustrate how current gu

43 rkers were merged into a highly AD-sensitive multimodality biomarker reflecting neural integrity.

44 uld lead to development of multidisciplinary/multimodality brain amyloidosis biomarkers that are reli

45 and systemic therapy that are part of modern multimodality breast cancer treatment can replace axilla

46 designed specifically for three-dimensional multimodality breast imaging could make possible some of

47 view, we explore the current applications of multimodality cardiac imaging in the diagnosis and monit

48 n and illustrate the use of state-of-the-art multimodality cardiac imaging to elucidate the pathophys

49 Multimodality cardiovascular imaging plays a central rol

50 h the goal of promoting the nascent field of multimodality cardiovascular molecular imaging.

51 on tomography and cardiac magnetic resonance multimodality characterization of the acutely infarcted,

52 ess for antibody-based agents, we designed a multimodality chelation (MMC) scaffold which combined a

53 t a customized dual-labeling approach with a multimodality chelation (MMC) scaffold would minimize st

54 ntial to quantitatively inform the design of multimodality clinical trials in genotype-defined cancer

55 The sensitivity of multimodality (computed tomography [CT], ultrasonography

56 biotic-impregnated ventricular catheters and multimodality, computerized systems allow ICP monitoring

57 ly, this approach may be applicable to other multimodality devices such as PET/MR.

58 Molecular imaging is a multimodality discipline for noninvasively visualizing b

59 have coalesced into a multidisciplinary and multimodality effort.

60 Multimodality evaluation of EBUS-TBNA can be successful

61 iques have unique strengths and synergies in multimodality evaluation of the patient with cognitive d

62 However, a postoperative multimodality evaluation, including a consultation with

63 However, a postoperative multimodality evaluation, including a consultation with

64 of tumor location and size to sophisticated multimodality exploration of molecular, physiologic, gen

65 Advances in multimodality gamma-cameras (SPECT/CT), algorithms for i

66 Conclusion: Our novel multimodality hybrid system has been successfully transl

67 , including three-dimensional image display, multimodality image fusion, quantitative measures, and i

68 nstalled a mass spectrometer in our Advanced Multimodality Image Guided Operating (AMIGO) suite and d

69 MIP-TF mouse beta-cells were multimodality imaged in models of type 1 and type 2 diab

70 inal phase (phase III), a public data set of multimodality images (CT, fluorine 18 fluorodeoxyglucose

71 The development of novel multimodality imaging agents and techniques represents t

72 Stimuli-responsive multimodality imaging agents have broad potential in med

73 Combining multimodality imaging allows visualization and quantific

74 lishment of task forces in emerging areas of multimodality imaging and critical care cardiology.

75 Aortic Bioprosthetic Valve Dysfunction With Multimodality Imaging and Its Treatment with Anticoagula

76 s of this study suggest that future clinical multimodality imaging and therapy with VEGF(121)/rGel ma

77 Our multimodality imaging approach is a valuable addition to

78 We have developed a multimodality imaging approach to monitor the transformi

79 Advances in multimodality imaging are enabling more accurate localiz

80 We present and test the use of multimodality imaging as a topological tool to map the a

81 All participants underwent multimodality imaging at baseline and month 12 and were

82 Multimodality imaging based on complementary detection p

83 having no cognitive impairment and underwent multimodality imaging between Oct 11, 2006, and Oct 5, 2

84 How multimodality imaging can be integrated in clinical mana

85 combined with CT has proven to be a valuable multimodality imaging device revealing both functional a

86 ion of intensity-modulated RT and the use of multimodality imaging for target volume and organs at ri

87 the strengths of different imaging methods, multimodality imaging has become an attractive strategy

88 The evolution of multimodality imaging has paralleled these developments.

89 ypes and to couple the use of biomarkers and multimodality imaging in early translational research st

90 Current guidelines addressing the role of multimodality imaging in IE are discussed.

91 Scientific statements recommend multimodality imaging in MINOCA to define the underlying

92 ew examines the current and emerging role of multimodality imaging in the evaluation of aortitis.

93 d; current guidelines address the use of the multimodality imaging in the field of IE with caution; t

94 In hypertrophic cardiomyopathy, multimodality imaging is crucial to confirm diagnosis, a

95 esult, a high index of suspicion followed by multimodality imaging is crucial, along with comprehensi

96 Multimodality imaging is indispensable for procedural gu

97 erapeutic components, targeting ligands, and multimodality imaging labels into one entity, termed "na

98 tant molecular target, melanin, into a novel multimodality imaging nanoplatform.

99 s recent progress in the design of PET-based multimodality imaging nanoprobes with an aim to overview

100 particles for cell labeling in vitro and for multimodality imaging of administered cells in vivo.

101 g for 8-12 weeks and underwent intracoronary multimodality imaging of an obstructive nonculprit lesio

102 Thus, multimodality imaging of experimental systemic infection

103 Multimodality imaging of tumor-bearing mice using biolum

104 sults realized the ability of this embedded, multimodality imaging platform to firstly detect biolumi

105 Multimodality imaging plays a pivotal role in the evalua

106 of the aorta in the trauma setting remains a multimodality imaging practice, and thus broad knowledge

107 QDs) are an attractive platform for building multimodality imaging probes, but the toxicity for typic

108 ssembly of various contrast agents to design multimodality imaging probes.

109 as stimulated growing interest in developing multimodality imaging probes.

110 Multimodality imaging provides a comprehensive evaluatio

111 Multimodality imaging reveals that iNSC delivery of the

112 Multimodality imaging ruled out the presence of a thromb

113 small-animal imaging, a less frequently used multimodality imaging strategy is the fusion of radionuc

114 ence after catheter ablation, and subsequent multimodality imaging studies have uncovered an inverse

115 In addition, multimodality imaging studies of dual-labeled model conj

116 igate the complementary information given in multimodality imaging studies of targeted therapeutics.

117 al indication and to independently interpret multimodality imaging studies.

118 us parts of patients' bodies, we applied our multimodality imaging system to investigate several diff

119 applications, and ongoing efforts to develop multimodality imaging systems that include DBT.

120 Multimodality imaging techniques play an integral role i

121 ation and quantitation of imaging variables, multimodality imaging technology, molecular and vascular

122 t multicentre study using novel non-invasive multimodality imaging to assess structural and inflammat

123 process, highlight the value of noninvasive multimodality imaging to assess the structural and funct

124 specific recommendations for utilization of multimodality imaging to optimize risk stratification an

125 Multimodality imaging using several reporter genes and i

126 Multimodality imaging was performed in AR42J xenografts.

127 le with ultrasound imaging, thereby enabling multimodality imaging with complementary contrast.

128 Multimodality imaging with coronary OCT and CMR identifi

129 rosclerotic disease using novel non-invasive multimodality imaging) study underwent fluorodeoxyglucos

130 siderable current interest to drug delivery, multimodality imaging, and electronic devices.

131 Exercise testing, multimodality imaging, and lower mean pressure gradient

132 Multimodality imaging, as represented by its greatest ex

133 eting, quantitative tumor uptake assessment, multimodality imaging, biodistribution and enhanced drug

134 entified in 84.5% (98/116) of the women with multimodality imaging, higher than with OCT alone (P<0.0

135 a culprit lesion, followed by intracoronary multimodality imaging, including optical coherence tomog

136 in the VX2 rabbit liver tumor model by using multimodality imaging, including single-snapshot radiogr

137 Continuing refinement in the capabilities of multimodality imaging, including ultrasound, computed to

138 Specifically, we address risk factors, multimodality imaging, pathophysiology, and novel treatm

139 comprehensive assessment with integration of multimodality imaging, testing, and clinical assessment.

140 was to test the hypothesis, with noninvasive multimodality imaging, that allogeneic mesenchymal stem

141 ase in the evaluation of cardiomyopathies is multimodality imaging, which is purported to be the effi

142 ed in this study, a subset of whom agreed to multimodality imaging.

143 epresent a novel contrast agent platform for multimodality imaging.

144 uct (SSTR2-EGFP) for nuclear and fluorescent multimodality imaging.

145 benefit to cardiac function as determined by multimodality imaging.

146 tumor-targeted monoclonal antibody probe for multimodality imaging.

147 therapy, MDSCs could be a novel component in multimodality immunotherapy targeting detrimental inflam

148 rotocol-driven neurointensive care utilizing multimodality in monitoring technology for patients with

149 Gaussian model for an accurate assessment of multimodality in zero-enriched expression data, (ii) a f

150 Use of multimodality intelligent workstations can improve the p

151 pleurectomy-decortication (P/D) as part of a multimodality lung-sparing treatment.

152 To assess the role of surgery in multimodality management of GISTs, we studied postoperat

153 Despite recent advances in multimodality management the prognosis of patients with

154 ro extension-distension data with full-field multimodality measurements of wall strain and thickness

155 The best performing multimodality model is a late fusion model that achieves

156 monstrated the power of coupling of HTS with multimodality molecular imaging and led to identificatio

157 Multimodality molecular imaging including SPECT, PET, ca

158 Development of reporter genes for multimodality molecular imaging is highly important.

159 We used multimodality molecular imaging to track the fate of inj

160 make ORCAFluors a promising new platform for multimodality molecular imaging.

161 rm with high selectivity and sensitivity for multimodality molecular imaging.

162 such thresholds should be optimized based on multimodality monitoring and individual brain physiology

163 Correlations between mean multimodality monitoring data and change-point analyses

164 This article reviews recent advances in multimodality monitoring of patients following severe he

165 ted whether electroencephalography (EEG) and multimodality monitoring parameters may facilitate asses

166 The literature supports the use of multimodality monitoring using all of the electrophysiol

167 ous surface (scalp) EEG (sEEG) recording and multimodality monitoring, including invasive measurement

168 olism can be simultaneously explored through multimodality MR imaging and PET imaging.

169 erging field of nanomedicine, many PET-based multimodality nanoparticle imaging agents have been deve

170 Nanoporphyrins can be used as amplifiable multimodality nanoprobes for near-infrared fluorescence

171 during esophagectomy for patients undergoing multimodality (neoadjuvant) therapy for adenocarcinoma o

172 uptake and either the single-modality or the multimodality neurodegenerative biomarkers.

173 highlight emerging trends such as the use of multimodality neuroimaging and the employment of 'deep l

174 Multimodality neuromonitoring plays an important role in

175 rend is for the application of the so-called multimodality neuromonitoring, which includes the use of

176 haracterize sickle cell cardiomyopathy using multimodality noninvasive cardiovascular testing and ide

177 Multimodality noninvasive imaging techniques were used t

178 l regulation can be exploited to control the multimodality of gene expression distributions in two-pr

179 gs inform the long-standing debate about the multimodality of mammalian granule cells and substantiat

180 uggested that M3S can accurately capture the multimodality on simulated and real single cell data.

181 th emphasis on the potential applications of multimodality optical and SPECT/PET systems.

182 This review provides a state-of-the-art, multimodality perspective spanning the multiple organ sy

183 racortical electroencephalographic (EEG) and multimodality physiological recordings in 48 comatose su

184 This article presents the construction of a multimodality platform that can be used for efficient de

185 ore robust than Gibbs sampling approaches to multimodality problems.

186 e question of how best to integrate TRT into multimodality protocols.

187 Several single institution series of multimodality radiochemotherapy have shown consistently

188 emerged as attractive platforms for building multimodality radiotracers for SPECT/MRI and PET/MRI.

189 This intensive multimodality regimen has resulted in a significant impr

190 Our results suggest that multimodality regimens including radical resection incre

191 is in vitro study provides evidence that our multimodality reporter construct can be used to study th

192 ggest that SAHA possibly could provide true, multimodality, salubrious effects for prevention and tre

193 ffective clinical operation of an integrated multimodality scanner setting.

194 FSM examinations presented for a prospective multimodality screening consisting of DM, WBUS, and MRI.

195 higher-order statistical features (kurtosis, multimodality) seem much harder to acquire.

196 low non-zero expressions, rationality of the multimodality setting, and the capability of LTMG in ext

197 The purpose of this study was to develop multimodality SPECT/MRI contrast agents for sentinel lym

198 A multimodality spectromicroscopy imaging system has been

199 body MRI (WB-MRI) could be an alternative to multimodality staging of colorectal cancer, but its diag

200 Multimodality strategies incorporating radiation or even

201 nagement is emerging as a multidisciplinary, multimodality strategy to address anemia and decrease bl

202 rwent complete resection by EPP as part of a multimodality strategy.

203 xperience is described in implementing a new multimodality stress test for accurate correlation of co

204 The proposed new multimodality stress test has the potential for simultan

205 ibility and potential effectiveness of novel multimodality stress testing.

206 in anatomic and functional image fusion from multimodality systems.

207 Among adults without known CVD, a novel multimodality testing strategy using left ventricular hy

208 The optimization of ES multimodality therapeutic strategies has resulted from t

209 Despite the use of multimodality therapeutics, it remains the second leadin

210 For multimodality therapies such as the combination of hyper

211 vidual risk factors, use of existing and new multimodality therapies that also address adherence, and

212 significant difference between surgery-based multimodality therapies; however, the largest estimated

213 Photodynamic and multimodality therapy also may become important componen

214 ptimal role for targeting FLT3 may depend on multimodality therapy and will likely require hematopoie

215 Using multimodality therapy before liver transplantation for h

216 vides rationale for further investigation of multimodality therapy combining kinase inhibitors with a

217 d 1- and 5-year survival from diagnosis with multimodality therapy compared with those not treated (7

218 Multimodality therapy consisted of hepatic resection, ra

219 reatments and an increase in experience with multimodality therapy continues to increase.

220 atified analysis revealed that surgery-based multimodality therapy demonstrated an improved survival

221 2 plasma samples from 18 subjects undergoing multimodality therapy for colorectal cancer.

222 In this analysis of multimodality therapy for elderly patients with GBM, OS

223 arkers may allow for real-time sequencing of multimodality therapy for individual patients based on a

224 Aggressive multimodality therapy for locally unresectable primary c

225 tively observed a child exposed to intensive multimodality therapy for metastatic neuroblastoma from

226 Multimodality therapy for patients with locally advanced

227 the primary modality therapy or as part of a multimodality therapy for primary breast lymphoma is ass

228 metry with the potential for single-agent or multimodality therapy for prostate cancer.

229 it can be used to augment both targeted and multimodality therapy for sarcoma.

230 atment sequencing allows patients to receive multimodality therapy in a manner that prioritizes early

231 ognosis and pathologic response with current multimodality therapy including an individualized surgic

232 concomitant chemotherapy usually as part of multimodality therapy including endoscopic resection and

233 Quality of life during and after multimodality therapy is considered as well as ongoing c

234 Multimodality therapy is required for the successful man

235 The goal of multimodality therapy is to minimize lifelong residual t

236 Multimodality therapy may help identify patients with le

237 ectively collected to evaluate the impact of multimodality therapy on posttransplant patient survival

238 tion arm, and 484 patients were treated with multimodality therapy or palliative therapy because of c

239 s that radiotherapy can be incorporated into multimodality therapy regimens beyond ADT, in combinatio

240 ttributed to the introduction of coordinated multimodality therapy through the efforts of collaborati

241 revents clinicians from providing aggressive multimodality therapy to the most appropriate individual

242 However, multimodality therapy used with curative intent is toxic

243 l CRP levels, radical tumor resection within multimodality therapy was associated with distinctly pro

244 Surgery-based multimodality therapy was associated with improved survi

245 ation of practice patterns demonstrated that multimodality therapy was most frequently administered i

246 istory of patients treated with contemporary multimodality therapy who underwent a positive margin PD

247 ntersect and overlap, so it is probable that multimodality therapy will be necessary for this disease

248 A standardized approach of multimodality therapy with intent-to-treat by transplant

249 As all patients undergoing NAT receive multimodality therapy, LN yield recommendations may not

250 With current multimodality therapy, nearly 90% of children with avera

251 Despite advances in surgical technique and multimodality therapy, rates of positive circumferential

252 PURPOSE OF REVIEW: Despite advances in multimodality therapy, the overall 5-year survival rate

253 y patients, who are often unable to tolerate multimodality therapy.

254 tion as the primary modality or as part of a multimodality therapy.

255 ed chemotherapy is regularly used as part of multimodality therapy.

256 h hepatocellular carcinoma were eligible for multimodality therapy.

257 than those treated with proctectomy alone or multimodality therapy.

258 diagnosis in most patients despite intensive multimodality therapy.

259 d cancer that is often fatal despite intense multimodality therapy.

260 g and alcohol consumption, and is treated by multimodality therapy.

261 of high-risk neuroblastoma is common despite multimodality therapy.

262 ce of R2 resections, and the frequent use of multimodality therapy.

263 patients with dMMR rectal cancers underwent multimodality therapy.

264 Approximately 715 patients underwent multimodality therapy; 231 patients were included in the

265 rain, and strain rate were analyzed by using multimodality tissue tracking from cine MR imaging.

266 ctor for survival and other end points after multimodality treatment and can serve as a parameter for

267 s in treatment, particularly with regards to multimodality treatment and newer systemic therapies for

268 eting agents have been incorporated into the multimodality treatment and shown promising response rat

269 ow CA19-9 monitoring should be used to guide multimodality treatment and what level of change in CA19

270 r lack thereof for components of the current multimodality treatment in subgroups of patients with no

271 This aggressive multimodality treatment is complex, not only regarding s

272 up A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was no

273 care in colon cancer and use of C stage for multimodality treatment planning and risk stratification

274 st be administered as part of a coordinated, multimodality treatment program.

275 Although this multimodality treatment provides higher response rates t

276 spective, multicenter, single-arm trial of a multimodality treatment regimen administered within a st

277 High-dose chemotherapy and multimodality treatment seemed to improve survival proba

278 only 54% of patients received chemotherapy; multimodality treatment was associated with improved sur

279 Today, with multimodality treatment, 50% of these patients will surv

280 In the era of multimodality treatment, a more refined tool is needed t

281 atomical considerations, initial assessment, multimodality treatment, and surgical approaches for the

282 ication of multidisciplinary assessment with multimodality treatment, including surgery, radiation an

283 Despite multimodality treatment, most high-grade gliomas eventua

284 ng-term survival of < 20% despite aggressive multimodality treatment.

285 ent surgery alone, and 159 patients received multimodality treatment.

286 mong patients who attained a CR status after multimodality treatment.

287 ne, and an additional 32 (2%) had a CR after multimodality treatment.

288 ovel ability to predict spheroid response to multimodality treatment.

289 n selected cases, personalized surgery-based multimodality treatments (MMT) have been shown to signif

290 outcomes in Group D retinoblastoma following multimodality treatments in a national retinoblastoma re

291 After multimodality treatments initiated with IVC, 50% of salv

292 ent morbidity because closure often requires multimodality treatments over a prolonged period of time

293 l prognosis, and survival benefits of recent multimodality treatments remain small.

294 foundation on which to build future phase II multimodality trials for stage I/II pancreatic cancer in

295 impression of the toxicity burden in complex multimodality trials.

296 vised analysis are labeled, and (2) 'genuine multimodality,' truly distinct solutions across replicat

297 rganizations are needed to quickly translate multimodality tumor angiogenesis imaging into multiple f

298 apy will be most effective in the context of multimodality tumor management.

299 post hoc correction were used to compare the multimodality VBD estimates.

300 of multifunctional polymers combines imaging multimodality with a biocompatible, tunable, and functio